Download the MIMS Education app now!
Overview
About this course
This educational module explores ALK-positive non-small cell lung cancer (NSCLC), a distinct molecular subtype associated with younger, non-smoking patients. With a focus on molecular pathogenesis, diagnostic testing, treatment evolution, and the latest evidence from the CROWN trial, learners will gain insights into optimal patient management using next-generation ALK inhibitors like lorlatinib.
The course highlights the unmet needs in ALK+ NSCLC, especially regarding central nervous system (CNS) involvement, and presents the 5-year efficacy and safety findings that support lorlatinib as a frontline option.
Learning Objectives:
By the end of this course, learners will be able to:
- Recognize the clinical characteristics and diagnostic criteria for ALK+ NSCLC.
- Understand the evolution of ALK-targeted therapies and resistance mechanisms.
- Evaluate the efficacy and safety data supporting lorlatinib use in ALK+ NSCLC.
- Apply real-world considerations in molecular testing and CNS disease management.
Topics covered
- Epidemiology and pathophysiology of ALK+ NSCLC and the role of ALK
- Diagnostic Testing for ALK
- Unmet Needs in ALK+ NSCLC
- CROWN Study Overview
- CROWN Study Efficacy Analysis
- CROWN Study Safety Analysis
- CROWN Study Dose Reduction 16-week Efficacy Analysis
- CROWN Study Genomic Analysis
- CROWN Study Summary
Sponsored by:
Something went wrong.